Issue
Human haematological and epithelial tumor-derived cell lines express distinct patterns of onco-microRNAs
Corresponding Author(s) : Flavia Biamonte
Cellular and Molecular Biology,
Vol. 63 No. 11: Issue 11
Abstract
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- (1) Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment and prognosis. AM J Cancer Res 2012; 2: 414-433.
- (2) Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Cur Med Chem. 2012; 19: 461-474.
- (3) Macfarlane LA,Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genomics 2010; 11: 537-561.
- (4) Shivdasani RA. MicroRNAs. regulators of gene expression and cell differentiation. Blood 2006; 108: 1646-1653.
- (5) Chen B,Li H, Zeng X, Yang P, Liu X, Zhao X, Liang S. Roles of microRNA on cancer cell metabolism. J Transl Med 2012; 10: 228.
- (6) Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-780.
- (7) Magenta A, Greco S, Gaetano C, Martelli F. Oxidative Stress and MicroRNAs in Vascular Diseases. Int J Mol Sci 2013; 14: 17319–17346.
- (8) Lee YS, Dutta A.MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199–227.
- (9) Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20:460-469.
- (10) Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor ? Cancer Metastasis Rev 2009; 28: 369-378.
- (11) Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12.
- (12) Riaz M, TM van Jaarsveld M, Hollestelle A, Prager-van der Smissen W, Heine AAJ, Boersma AWM, Liu J, Helmijr J, Ozturk B, Smid M, Wiemer EA, Foekens JA, Martens JWM. MiRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 2013; 15: R33.
- (13) Zolea F, Biamonte F, Candeloro P, Di Sanzo M, Cozzi A, Di Vito A, Quaresima B, Lobello N, Trecroci F, Di Fabrizio E, Levi S, Cuda G, Costanzo F.H ferritin silencing induces protein misfolding in K562 cells: A Raman analysis.Free Radic Biol Med 2015; 89: 614-623.
- (14) Biamonte F, Zolea F, Bisognin A, Di Sanzo M, Saccoman C, Scumaci D, Aversa I, Panebianco M, Faniello MC, Bortoluzzi S, Cuda G, Costanzo F. H-Ferritin-Regulated MicroRNAs Modulate Gene Expression in K562 Cells. Plos One 2015; 10:e0122105.
- (15) McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263–1284.
- (16) Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 2007; 39: 655-660.
- (17) Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adélaí¯de J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia 2009; 23: 583-585.
- (18) Cleveland SM, Smith S, Tripathi R, Mathias EM, Goodings C, Elliott N, Peng D, El-Rifai W, Yi D, Chen X, Li L, Mullighan C, Downing JR, Love P, Davé UP. Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia. Stem Cells 2013; 31: 882-894.
- (19) Kent DG, Copley MR, Benz C, Wöhrer S, Dykstra BJ, Ma E, Cheyne J, Zhao Y, Bowie MB, Zhao Y, Gasparetto M, Delaney A, Smith C, Marra M, Eaves CJ. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 2009; 113: 6342-6350.
- (20) Machado-Neto JA, Saad ST, Traina F. Stathmin 1 in normal and malignant hematopoiesis BMB Rep 2014; 47: 660-665.
- (21) Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, Yang Y, Cai K, Ruan X, Yan J, Hu S, Fang X. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genom Proteom Bioin 2014; 12: 79-91.
- (22) Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E, Keller A. Distribution of miRNA expression across human tissues. Nucleic Acids Res 2016; 44: 3865-3877.
- (23) Lin F, Yao L, Xiao J, Liu D, Ni Z. MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther. 2014; 7: 1583-1591.
- (24) Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC, Li L. miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. Int J Clin Exp Med. 2015; 8: 9107-9113.
- (25) Ke Y, Zhao W, Xiong J, Cao R. miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int. 2013; 2013: 506731.
- (26) Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D, Olayioye MA. miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res. 2014; 74: 5256-5265.
- (27) Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013; 11: 1051-1060.
- (28) Gong Y, Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.World J Gastroenterol. 2015; 21: 2949–2958.
- (29) Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z. Decrease of miR-202-3p Expression, a Novel Tumor Suppressor, in Gastric Cancer. PLoS One 2013; 8: e69756.
- (30) Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, Zhu B, Ju S. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 2014; 51: 543-549.
- (31) Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
- (32) Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-220.
- (33) Chen D, Li Y, Yu Z, Su Z, Yu W, Li Y, Yang S, Gui Y, Ni L, Lai Y. Upregulated microRNA-16 as an oncogene in renal cell carcinoma. Mol Med Rep 2015; 12: 1399-13404.
- (34) Zhu Y, Xia Y, Niu H, Chen Y: MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma. Cell Physiol Biochem 2014; 33: 1340-1348.
- (35) Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008; 451: 1125-1129.
- (36) Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104: 19971-19976.
- (37) Fuziwara CS, Kimura ET. Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer. Front Med (Lausanne) 2015; 2: 64.
- (38) Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-220.
- (39) Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
- (40) Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296-306.
- (41) Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H.miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-4271.
- (42) Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X, Wan XP. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol. 2013; 30: 484.
- (43) Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, Wang J.Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Gene 2017; 607:41-46.
- (44) Li Q, Wu Y, Zhang J, Yi T, Li W.MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia. Am J Transl Res 2016; 8: 955–967.
- (45) Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JEJ. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010; 95: 1325–1333.
- (46) Undi RB, Kandi R, Gutti RK. MicroRNAs as Haematopoiesis Regulators. Adv Hematol 2013; 2013: 695754.
- (47) Su J, Zhang A, Shi Z, Ma F, Pu P, Wang T, Zhang J, Kang C, Zhang Q. MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int J Oncol 2012; 40: 1162-70.
- (48) Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z. Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One 2013; 8: e69756.
- (49) Gong Y,Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. World J Gastroenterol 2015; 21: 2949-2958.
- (50) Paudel D, Zhou W, Ouyang Y, Dong S, Huang Q, Giri R, Wang J, Tong X. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer. Gene 2016; 586: 48-55.
- (51) He Z, Yi J, Liu X, Chen J, Han S, Jin L, Chen L, Song H. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 2016; 15: 51.
- (52) Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel non invasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013; 22: 540-548.
- (53) Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF. Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press) 2015; 7: 59-79.
References
(1) Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment and prognosis. AM J Cancer Res 2012; 2: 414-433.
(2) Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Cur Med Chem. 2012; 19: 461-474.
(3) Macfarlane LA,Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genomics 2010; 11: 537-561.
(4) Shivdasani RA. MicroRNAs. regulators of gene expression and cell differentiation. Blood 2006; 108: 1646-1653.
(5) Chen B,Li H, Zeng X, Yang P, Liu X, Zhao X, Liang S. Roles of microRNA on cancer cell metabolism. J Transl Med 2012; 10: 228.
(6) Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-780.
(7) Magenta A, Greco S, Gaetano C, Martelli F. Oxidative Stress and MicroRNAs in Vascular Diseases. Int J Mol Sci 2013; 14: 17319–17346.
(8) Lee YS, Dutta A.MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199–227.
(9) Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20:460-469.
(10) Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor ? Cancer Metastasis Rev 2009; 28: 369-378.
(11) Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12.
(12) Riaz M, TM van Jaarsveld M, Hollestelle A, Prager-van der Smissen W, Heine AAJ, Boersma AWM, Liu J, Helmijr J, Ozturk B, Smid M, Wiemer EA, Foekens JA, Martens JWM. MiRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 2013; 15: R33.
(13) Zolea F, Biamonte F, Candeloro P, Di Sanzo M, Cozzi A, Di Vito A, Quaresima B, Lobello N, Trecroci F, Di Fabrizio E, Levi S, Cuda G, Costanzo F.H ferritin silencing induces protein misfolding in K562 cells: A Raman analysis.Free Radic Biol Med 2015; 89: 614-623.
(14) Biamonte F, Zolea F, Bisognin A, Di Sanzo M, Saccoman C, Scumaci D, Aversa I, Panebianco M, Faniello MC, Bortoluzzi S, Cuda G, Costanzo F. H-Ferritin-Regulated MicroRNAs Modulate Gene Expression in K562 Cells. Plos One 2015; 10:e0122105.
(15) McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263–1284.
(16) Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 2007; 39: 655-660.
(17) Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adélaí¯de J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia 2009; 23: 583-585.
(18) Cleveland SM, Smith S, Tripathi R, Mathias EM, Goodings C, Elliott N, Peng D, El-Rifai W, Yi D, Chen X, Li L, Mullighan C, Downing JR, Love P, Davé UP. Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia. Stem Cells 2013; 31: 882-894.
(19) Kent DG, Copley MR, Benz C, Wöhrer S, Dykstra BJ, Ma E, Cheyne J, Zhao Y, Bowie MB, Zhao Y, Gasparetto M, Delaney A, Smith C, Marra M, Eaves CJ. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 2009; 113: 6342-6350.
(20) Machado-Neto JA, Saad ST, Traina F. Stathmin 1 in normal and malignant hematopoiesis BMB Rep 2014; 47: 660-665.
(21) Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, Yang Y, Cai K, Ruan X, Yan J, Hu S, Fang X. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genom Proteom Bioin 2014; 12: 79-91.
(22) Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E, Keller A. Distribution of miRNA expression across human tissues. Nucleic Acids Res 2016; 44: 3865-3877.
(23) Lin F, Yao L, Xiao J, Liu D, Ni Z. MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther. 2014; 7: 1583-1591.
(24) Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC, Li L. miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. Int J Clin Exp Med. 2015; 8: 9107-9113.
(25) Ke Y, Zhao W, Xiong J, Cao R. miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int. 2013; 2013: 506731.
(26) Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D, Olayioye MA. miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res. 2014; 74: 5256-5265.
(27) Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013; 11: 1051-1060.
(28) Gong Y, Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.World J Gastroenterol. 2015; 21: 2949–2958.
(29) Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z. Decrease of miR-202-3p Expression, a Novel Tumor Suppressor, in Gastric Cancer. PLoS One 2013; 8: e69756.
(30) Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, Zhu B, Ju S. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 2014; 51: 543-549.
(31) Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
(32) Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-220.
(33) Chen D, Li Y, Yu Z, Su Z, Yu W, Li Y, Yang S, Gui Y, Ni L, Lai Y. Upregulated microRNA-16 as an oncogene in renal cell carcinoma. Mol Med Rep 2015; 12: 1399-13404.
(34) Zhu Y, Xia Y, Niu H, Chen Y: MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma. Cell Physiol Biochem 2014; 33: 1340-1348.
(35) Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008; 451: 1125-1129.
(36) Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104: 19971-19976.
(37) Fuziwara CS, Kimura ET. Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer. Front Med (Lausanne) 2015; 2: 64.
(38) Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-220.
(39) Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
(40) Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296-306.
(41) Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H.miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-4271.
(42) Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X, Wan XP. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol. 2013; 30: 484.
(43) Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, Wang J.Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Gene 2017; 607:41-46.
(44) Li Q, Wu Y, Zhang J, Yi T, Li W.MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia. Am J Transl Res 2016; 8: 955–967.
(45) Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JEJ. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010; 95: 1325–1333.
(46) Undi RB, Kandi R, Gutti RK. MicroRNAs as Haematopoiesis Regulators. Adv Hematol 2013; 2013: 695754.
(47) Su J, Zhang A, Shi Z, Ma F, Pu P, Wang T, Zhang J, Kang C, Zhang Q. MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int J Oncol 2012; 40: 1162-70.
(48) Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z. Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One 2013; 8: e69756.
(49) Gong Y,Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. World J Gastroenterol 2015; 21: 2949-2958.
(50) Paudel D, Zhou W, Ouyang Y, Dong S, Huang Q, Giri R, Wang J, Tong X. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer. Gene 2016; 586: 48-55.
(51) He Z, Yi J, Liu X, Chen J, Han S, Jin L, Chen L, Song H. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 2016; 15: 51.
(52) Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel non invasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013; 22: 540-548.
(53) Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF. Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press) 2015; 7: 59-79.